Elsie Biotechnologies, Inc., a biopharmaceutical company unlocking the full potential of oligonucleotide therapeutics, entered into a research collaboration agreement with GSK plc to advance the discovery and development of Elsie’s oligonucleotide discovery platform with the aim of finding novel oligonucleotides optimized for safety, efficacy, and delivery. Elsie will receive an upfront collaboration payment from GSK to conduct initial research activities. Upon exercising the option during th...